Goswami, Sangeeta
Walle, Thomas http://orcid.org/0000-0003-4835-955X
Cornish, Andrew E.
Basu, Sreyashi
Anandhan, Swetha
Fernandez, Irina
Vence, Luis
Blando, Jorge
Zhao, Hao
Yadav, Shalini Singh
Ott, Martina
Kong, Ling Y.
Heimberger, Amy B. http://orcid.org/0000-0002-9970-8695
de Groot, John
Sepesi, Boris
Overman, Michael
Kopetz, Scott
Allison, James P.
Pe’er, Dana
Sharma, Padmanee http://orcid.org/0000-0003-4658-055X
Funding for this research was provided by:
Parker Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 19 November 2018
Accepted: 11 November 2019
First Online: 23 December 2019
Competing interests
: P.S. has ownership in Jounce Therapeutics, Neon, Constellation, Oncolytics Biotech, BioAtla, Forty Seven, Apricity, Polaris, Marker Therapeutics, Codiak BioSciences, ImaginAb, Dragonfly, Lytix Biopharma and Hummingbird. P.S. serves as a consultant for Constellation, Jounce Therapeutics, Neon, BioAtla, Pieris Pharmaceuticals, Oncolytics Biotech, Forty Seven, Polaris, Apricity, Marker Therapeutics, Codiak BioSciences, ImaginAb, Dragonfly, Lytix Biopharma and Hummingbird.